Indivior INDV 深 沪
已收盘 11-02 16:00:00 美东时间
36.28
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 36.28
- 总市值 42.82亿
- 52周最高 34.68
- 市盈率 静 22.11
- 换手率 0.00%
- 52周最低 19.55
- 委 比 0.00%
- 总股本 1.18亿
- 历史最高 34.68
- 量 比 0
- 振 幅 0.00%
- 历史最低 -0.80
- 每 手 1
- 风险率 2.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
Supernus, Inc.'s CEO, Jack A. Khattar, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London on November 16, 2026. Investors can access a live audio webcast or archived replay via the company's website. Supernus specializes in developing and commercializing treatments for CNS diseases, with a portfolio addressing various conditions. The press release also includes forward-looking statements about the com...
11-10 13:30
INDV收涨2.57%，成交额1.77亿美元
11月5日，INDV（INDV）收涨2.57%，报36.28美元，成交额1.77亿美元，市值42.82亿美元。 行情数据 • 开盘价：35.43美元 • 最高价...
11-05 06:09
Supernus–Indivior Deal Faces Dividend Financing Risk as Citibank Term Loan Remains Uncertain
Supernus Pharmaceuticals (SUPN) has disclosed a new risk, in the Debt & Fin...
10-31 14:01
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript
Supernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www...
10-30 05:23
Supernus Pharmaceuticals (SUPN) 2026年第三季度业绩电话会议：营收增长、上调业绩指引及Indivior合并
Supernus Pharmaceuticals 2026财年第三季度财报电话会议涵盖了18%的营收增长、更强劲的产品销售、上调的独立业绩指引以及与 Indivior 尚待完成的合并案。
10-29 21:45
财报速睇 | Indivior 2026财年Q3营收3.56亿美元，同比增长13.4%；归母净利润1.37亿美元，同比增长226.2%
华盛资讯10月29日讯，Indivior公布2026财年Q3业绩，公司Q3营收3.56亿美元，同比增长13.4%，归母净利润1.37亿美元，同比增长226.2%。
10-29 21:19
Indivior Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.
Indivior Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.
10-29 21:05
财报速睇 | Indivior 2026财年Q3营收3.56亿美元，同比增长13.4%；归母净利润1.37亿美元，同比增长226.2%
华盛资讯10月29日讯，Indivior公布2026财年Q3业绩，公司Q3营收3.56亿美元，同比增长13.4%，归母净利润1.37亿美元，同比增长226.2%。
10-29 20:34
美股大行评级 | 潜在涨幅163.5%！BTIG上调Cullinan Therapeutics目标价至41美元，维持"买入"评级
今日重点评级关注：BTIG：维持Cullinan Therapeutics"买入"评级，目标价从40美元升至41美元；Rosenblatt：维持SK海力士"买入"评级，目标价从320美元升至400美元
10-29 12:30
Barclays Maintains Overweight on Indivior Pharmaceuticals, Raises Price Target to $45
Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and raises the price target from $43 to $45.
10-28 23:42
